Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
|
10.01.03 |
Drugs which suppress the rheumatic disease process |
|
|
10.01.03 |
Gold |
|
|
10.01.03 |
Penicillamine |
|
|
10.01.03 |
Antimalarials |
|
|
10.01.03 |
Drugs affecting the immune response |
|
|
Azathioprine
(Rheumatology)
|
Restricted

|
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- RNOH:
- Restricted to Rheumatology Consultants ONLY
- See links below
- UCLH:
- WH:
|
NCL JFC: DMARD Quick Reference Guide for Primary Care Prescribers
RNOH + Herts CCG: Adult Rheumatology Shared Care - Principles and Responsibilities
RNOH + Herts CCG: Azathioprine in Adult Rheumatology - Shared Care Information
|
Ciclosporin
(Rheumatology)
|
Restricted

|
NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Deximune® is the preferred brand
- RNOH:
- Restricted to Rheumatology Consultants ONLY
- See links below
- UCLH:
- WH:
|
NCL JFC: DMARD Quick Reference Guide for Primary Care Prescribers
RNOH + Herts CCG: Adult Rheumatology Shared Care - Principles and Responsibilities
RNOH + Herts CCG: Ciclosporin in Adult Rheumatology - Shared Care Information
|
Cyclophosphamide
(Scleroderma, Vasculitis, SLE, Sarcoid)
|
Restricted
|
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- Approved for use in Scleroderma (lung fibrosis), Vasculitis, SLE and Sarcoid
- RNOH:
- UCLH:
- WH:
|
|
Leflunomide
(Rheumatology)
|
Restricted

|
Provider notes
- NMUH:
- Restricted to Rheumatology Consultants ONLY
- RFL:
- RNOH:
- Restricted to Rheumatology Consultants ONLY
- See links below
- UCLH:
- WH:
- Restricted to Rheumatology Consultants ONLY
|
NCL JFC: Rheumatoid arthritis DMARD and high-cost drug pathway
RNOH + Herts CCG: Adult Rheumatology Shared Care - Principles and Responsibilities
RNOH + Herts CCG: Leflunomide in Adult Rheumatology - Shared Care Information
|
Methotrexate SC / IM injection
(Rheumatology)
|
Restricted

|
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
The licensed routes of administration for parenteral preparations vary—further information can be found in the product literature for the individual preparations.
Provider notes
- NMUH:
- RFL:
- Metoject brand available in a variety of strengths
- See pharmacy policy for the safe dispensing of methotrexate
- RNOH:
- Rheumatology Consultants ONLY
- Metoject and Nordimet (if autoinjector required) brand
- See links below
- UCLH:
- WH:
|
RNOH + Herts CCG: Adult Rheumatology Shared Care - Principles and Responsibilities
RNOH + Herts CCG: Methotrexate in Adult Rheumatology - Shared Care Information
|
Methotrexate tablets
(Rheumatology)
|
Restricted

|
NOTE: There is more than one monograph for Methotrexate, click here to search for formulary status and its use for other indications.
Provider notes
- NMUH:
- RFL:
- 2.5mg tablets only
- See pharmacy policy for safe dispensing of methotrexate
- RNOH:
- Restricted for Rheumatology Consultants ONLY
- 2.5mg tablets ONLY
- See links below
- UCLH:
- WH:
|
NCL JFC: Rheumatoid arthritis DMARD and high-cost drug pathway
NCL JFC: Shared care Guideline - Prescribing and Monitoring of oral methotrexate for licensed and off-label indications
RNOH + Herts CCG: Adult Rheumatology Shared Care - Principles and Responsibilities
RNOH + Herts CCG: Methotrexate in Adult Rheumatology - Shared Care Information
|
|
|
|
10.01.03 |
Cytokine modulators |
|
|
10.01.03 |
Sulfasalazine |
|
|
.... |
Key |
Traffic Light Status Information
Status |
Description |
 
|
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity. |
 
|
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf |
 
|
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data. |
|
|
|